Oncology Xagena
Results from the phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational Sotorasib ( AMG 510 ) in 126 patients with KRAS G12C-mutated advanced non-small cell lung cancer ( NSCLC ...
New data from the phase 1 CHRYSALIS study, which has evaluated Amivantamab in patients with metastatic or unresectable non-small cell lung cancer ( NSCLC ) and epidermal growth factor receptor ( EGFR ...
Updated data from GARNET cohort F evaluating Dostarlimab in mismatch repair-deficient ( dMMR ) non-endometrial advanced solid cancers were presented at the 2021 American Society of Clinical Oncology ...
Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly with the advent of immunotherapy. However, the association between autoimmune disease and ...
NICOLAS is the first completed single-arm phase II trial in stage III non-small-cell lung cancer ( NSCLC ) examining hierarchically first the safety and then the efficacy of adding Nivolumab ( Opdivo ...
Consolidation Durvalumab after chemoradiation ( CRT ) is the current standard of care for locally advanced non-small-cell lung cancer ( NSCLC ). Researchers have hypothesized that adding immunothe ...
Non-small-cell lung cancer ( NSCLC ) is terminal in most patients with locally advanced stage disease. Researchers have assessed the antitumour activity and safety of neoadjuvant chemoimmunotherapy ...
Sintilimab ( Tyvyt ), an anti–programmed death 1 antibody, plus Pemetrexed and Platinum had revealed promising efficacy for nonsquamous non-small-cell lung cancer ( NSCLC ) in a phase 1b study. Re ...
Researchers have retrospectively examined progression-free survival ( PFS ) and response by ALK fluorescence in-situ hybridization ( FISH ) status in patients with advanced ALK immunohistochemistry ( ...
In the randomized KEYNOTE-407 study, Pembrolizumab ( Keytruda ) plus Carboplatin and Paclitaxel / nab-Paclitaxel ( chemotherapy ) has significantly improved overall survival ( OS ) and progression-fre ...
Osimertinib ( Tagrisso ) is standard-of-care therapy for previously untreated epidermal growth factor receptor ( EGFR ) mutation–positive advanced non–small-cell lung cancer ( NSCLC ). The efficacy ...
The efficacy and safety of the anti–programmed death ligand 1 ( PD-L1 ) monoclonal antibody Atezolizumab ( Tecentriq ), as compared with those of Platinum-based chemotherapy, as first-line treatment ...
Five-year survival results from the pivotal phase 3 KEYNOTE-024 trial were presented at ESMO Virtual Congress 2020. Sustained, long-term survival benefit and durable responses with Pembrolizumab ( ...
The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib ( Xalkori ) in treatment-naive ALK-positive non-small-cell lung c ...
According to phase II trial PRINCEPS, no safety signals were raised, no major toxicity and no surgery impairment were reported following one cycle of neoadjuvant Atezolizumab ( Tecentriq ) therapy in ...
